You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

CD19 (cluster of differentiation antigen) 19

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Lymphoma, B-Cell, Lymphoma, Non-hodgkins, Chronic Lymphocytic Leukemia Trial run by the NCI (Anti-cluster of differentiation 19

Terminated
Has Results
  • Lymphoma, B-Cell
  • +3 more
  • Anti-cluster of differentiation 19 (CD19)-Chimeric Antigen Receptors (CAR) and Anti-cluster of differentiation 20 (CD20)-CAR T cells
  • +2 more
  • Bethesda, Maryland
    National Institutes of Health Clinical Center
Jan 26, 2022

Primary Mediastinal B-cell Lymphoma, Diffuse, Large B-cell Lymphoma, DLBCL Transformed From Follicular Lymphoma Trial run by the

Completed
Has Results
  • Primary Mediastinal B-cell Lymphoma
  • +3 more
  • Bethesda, Maryland
    National Institutes of Health Clinical Center, 9000 Rockville Pi
Dec 29, 2021

CD19+ Malignancies: Relapse Post-allogeneic Transplant Trial in London (Infusion of modified CAR19 T-cells (4G7-CARD T-cells))

Active, not recruiting
  • CD19+ Malignancies: Relapse Post-allogeneic Transplant
  • Infusion of modified CAR19 T-cells (4G7-CARD T-cells)
  • London, United Kingdom
    University College London Hospital
Jun 16, 2021

Systemic Lupus Erythematosus (SLE) Trial in Shanghai (anti-CD19 CAR NK cells (KN5501))

Recruiting
  • Systemic Lupus Erythematosus (SLE)
  • anti-CD19 CAR NK cells (KN5501)
  • Shanghai, China
    Changhai Hospital
Aug 25, 2023

Multiple Sclerosis, Multiple Sclerosis, Primary Progressive, Multiple Sclerosis, Secondary Progressive Trial in Palo Alto

Not yet recruiting
  • Multiple Sclerosis
  • +2 more
  • KYV-101 anti-CD19 CAR-T cell therapy
  • Standard lymphodepletion regimen
  • Palo Alto, California
    Stanford Multiple Sclerosis Center
Nov 13, 2023

Lupus Nephritis, Lupus Nephritis - World Health Organization (WHO) Class III, Lupus Nephritis - WHO Class IV Trial in Denver,

Recruiting
  • Lupus Nephritis
  • +2 more
  • KYV-101 anti-CD19 CAR-T cell therapy
  • Standard lymphodepletion regimen
  • Denver, Colorado
  • +1 more
Jul 7, 2023

Diffuse Large B Cell Lymphoma, Primary Mediastinal Large B Cell Lymphoma, Large B-cell Lymphoma Trial in Kaohsiung, Taipei

Recruiting
  • Diffuse Large B Cell Lymphoma
  • +4 more
  • CD19-targeted chimeric antigen receptor T-cell
  • Kaohsiung, Taiwan
  • +2 more
Oct 25, 2022

Tumors, Hematologic Tumors, Hematologic Diseases Trial in Xuzhou (RD13-02 cell infusion)

Recruiting
  • Neoplasms
  • +2 more
  • RD13-02 cell infusion
  • Xuzhou, Jiangsu, China
    Affiliated hospital of Xuzhou medical college
Jun 7, 2023

SLE (Systemic Lupus) Trial in Bangkok (CAR T-cell therapy)

Not yet recruiting
  • SLE (Systemic Lupus)
  • CAR T-cell therapy
  • Bangkok, Please Select, Thailand
    King Chulalongkorn Memorial Hospital
Nov 23, 2023

Diffuse Large B Cell Lymphoma Trial in Hangzhou (Autologous humanized anti-CD19 and anti-CD20 dual specific CAR-T Cells)

Unknown status
  • Diffuse Large B Cell Lymphoma
  • Autologous humanized anti-CD19 and anti-CD20 dual specific CAR-T Cells
  • Hangzhou, Zhejiang, China
    First Affiliated Hospital of Zhejiang University
Aug 25, 2020

Non-hodgkin Lymphoma,B Cell Trial in Beijing (Autologous CD19-STAR-T cell, Fludarabine, Cyclophosphamide)

Recruiting
  • Non-hodgkin Lymphoma,B Cell
  • Autologous CD19-STAR-T cell
  • +2 more
  • Beijing, Beijing, China
  • +1 more
Nov 21, 2022

Relapsed or Refractory CD19+ B-cell Lymphoma, Relapsed or Refractory Chronic Lymphocytic Leukemia, Relapsed or Refractory Small

Recruiting
  • Relapsed or Refractory CD19+ B-cell Lymphoma
  • +2 more
  • TBI-2001
  • +2 more
  • Toronto, Ontario, Canada
    Princess Margaret Cancer Centre
Jul 26, 2023

ALL, B Cell Lymphoma, Leukemia Trial run by the NCI (Anti-Cluster of Differentiation (CD)19-Chimeric antigen receptor (CAR))

Completed
Has Results
  • ALL
  • +4 more
  • Anti-Cluster of Differentiation (CD)19-Chimeric antigen receptor (CAR)
  • Bethesda, Maryland
    National Institutes of Health Clinical Center, 9000 Rockville Pi
Aug 14, 2020

B-cell NHL, CLL Trial (CARCIK-CD19)

Not yet recruiting
  • B-cell NHL
  • CLL
  • CARCIK-CD19
  • (no location specified)
May 19, 2023

Refractory Non-Hodgkin Lymphoma, Burkitt Lymphoma, Mantle Cell Lymphoma Trial in San Francisco (Fludarabine, Cyclophosphamide,

Recruiting
  • Refractory Non-Hodgkin Lymphoma
  • +8 more
  • San Francisco, California
    University of California, San Francisco
May 2, 2022

Chronic Lymphocytic Leukemia, B-Cell Chronic Lymphocytic Leukemia, Lymphoma, B-Cell Trial run by the National Cancer Institute

Not yet recruiting
  • Chronic Lymphocytic Leukemia
  • +2 more
  • Anti-CD19 and anti-CD20 bicistronic CAR T- cells
  • +2 more
  • Bethesda, Maryland
    National Institutes of Health Clinical Center
Apr 10, 2023

B-cell Acute Lymphoblastic Leukemia Trial in Seoul (SNUH-CD19-CAR-T)

Recruiting
  • B-cell Acute Lymphoblastic Leukemia
  • SNUH-CD19-CAR-T
  • Seoul, Korea, Republic of
    Seoul National University Hospital
Feb 20, 2022

Lymphoma, Non-Hodgkin, Diffuse Large B Cell Lymphoma Trial in Tianjin (CD19-targeted Chimeric Antigen Receptor(CAR) T Cells)

Recruiting
  • Lymphoma, Non-Hodgkin
  • Diffuse Large B Cell Lymphoma
  • CD19-targeted Chimeric Antigen Receptor(CAR) T Cells
  • Tianjin, Tianjin, China
    Tianjin Cancer Hospital
Nov 19, 2023

SLE (Systemic Lupus), Sjogren's Syndrome, Systemic Scleroderma Trial in Taiyuan (CD19 targeted CAR-T cells)

Recruiting
  • SLE (Systemic Lupus)
  • +4 more
  • CD19 targeted CAR-T cells
  • Taiyuan, Shanxi, China
    Shanxi Bethune Hospital
Sep 25, 2023

Non Hodgkin's Lymphoma Trial in Beijing (Allogenic CD19-CAR-?dT cell, Fludarabine, Cyclophosphamide)

Recruiting
  • Non Hodgkin's Lymphoma
  • Allogenic CD19-CAR-γδT cell
  • +2 more
  • Beijing, Beijing, China
  • +1 more
Jan 31, 2023

CD 19+ Acute Leukemia Trial in Seattle (T-cell Antigen Presenting Cells expressing truncated CD19 (T-APC))

Active, not recruiting
  • CD 19+ Acute Leukemia
  • T-cell Antigen Presenting Cells expressing truncated CD19 (T-APC)
  • Seattle, Washington
    Seattle Children's Hospital
Mar 22, 2022

Lymphoblastic Leukemia, Lymphoblastic Leukemia in Children, Lymphoblastic Leukemia, Acute Adult Trial in Singapore (Anti-CD19

Recruiting
  • Lymphoblastic Leukemia
  • +5 more
  • Anti-CD19 CAR T-cells
  • Singapore, Singapore
  • +1 more
Dec 4, 2022

Acute Lymphoblastic Leukemia in Remission Trial in Suzhou (CD19 CAR-T cells and CD19 positive feeder T cells)

Recruiting
  • Acute Lymphoblastic Leukemia in Remission
  • CD19 CAR-T cells and CD19 positive feeder T cells
  • Suzhou, Jiangsu, China
  • +2 more
May 18, 2022

19 and 22+ B Cell Hematologic Tumors Trial in Wuhan (Autologous CD19/CD22 Chimeric Antigen Receptor T-cells)

Recruiting
  • 19 and 22+ B Cell Hematologic Tumors
  • 19 and 20+ B Cell Hematologic Tumors
  • Autologous CD19/CD22/CD20 Chimeric Antigen Receptor T-cells
  • Wuhan, Hubei, China
    Tongji Hospital
Jan 11, 2023

Relapsed/ Refractory Multiple Myeloma Trial (GC012F)

Not yet recruiting
  • Relapsed/ Refractory Multiple Myeloma
  • GC012F
  • (no location specified)
Apr 28, 2023